• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    2/10/26 4:25:59 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DVAX alert in real time by email
    S-8 POS 1 d140298ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on February 10, 2026

    Registration No. 333-113220

    Registration No. 333-136345

    Registration No. 333-145094

    Registration No. 333-152819

    Registration No. 333-157741

    Registration No. 333-164255

    Registration No. 333-171552

    Registration No. 333-190313

    Registration No. 333-197838

    Registration No. 333-204506

    Registration No. 333-211747

    Registration No. 333-218470

    Registration No. 333-221832

    Registration No. 333-225525

    Registration No. 333-233247

    Registration No. 333-241674

    Registration No. 333-253515

    Registration No. 333-258469

    Registration No. 333-265373

    Registration No. 333-281307

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    FORM S-8 REGISTRATION STATEMENT NO. 333-113220

    FORM S-8 REGISTRATION STATEMENT NO. 333-136345

    FORM S-8 REGISTRATION STATEMENT NO. 333-145094

    FORM S-8 REGISTRATION STATEMENT NO. 333-152819

    FORM S-8 REGISTRATION STATEMENT NO. 333-157741

    FORM S-8 REGISTRATION STATEMENT NO. 333-164255

    FORM S-8 REGISTRATION STATEMENT NO. 333-171552

    FORM S-8 REGISTRATION STATEMENT NO. 333-190313

    FORM S-8 REGISTRATION STATEMENT NO. 333-197838

    FORM S-8 REGISTRATION STATEMENT NO. 333-204506

    FORM S-8 REGISTRATION STATEMENT NO. 333-211747

    FORM S-8 REGISTRATION STATEMENT NO. 333-218470

    FORM S-8 REGISTRATION STATEMENT NO. 333-221832

    FORM S-8 REGISTRATION STATEMENT NO. 333-225525

    FORM S-8 REGISTRATION STATEMENT NO. 333-233247

    FORM S-8 REGISTRATION STATEMENT NO. 333-241674

    FORM S-8 REGISTRATION STATEMENT NO. 333-253515

    FORM S-8 REGISTRATION STATEMENT NO. 333-258469

    FORM S-8 REGISTRATION STATEMENT NO. 333-265373

    FORM S-8 REGISTRATION STATEMENT NO. 333-281307

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Dynavax Technologies Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   33-0728374

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    2100 Powell Street, Suite 720

    Emeryville, CA

      94608
    (Address of Principal Executive Offices)   (Zip Code)

    Dynavax Technologies Corporation1997 Equity Incentive Plan

    Dynavax Technologies Corporation 2004 Stock Incentive Plan

    Dynavax Technologies Corporation 2004 Employee Stock Purchase Plan

    Dynavax Technologies Corporation 2010 Employee Inducement Award Plan

    Dynavax Technologies Corporation 2011 Equity Incentive Plan, as amended and restated

    Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan, as amended and restated

    Dynavax Technologies Corporation 2017 Inducement Award Plan

    Dynavax Technologies Corporation 2018 Equity Incentive Plan, as amended and restated

    Dynavax Technologies Corporation 2021 Inducement Award Plan

    (Full title of the plan)

    Thomas Grenier

    Vice President

    Dynavax Technologies Corporation

    2100 Powell Street, Suite 720

    Emeryville, CA 94608

    (510) 665-4618

    (Name, address and telephone number of agent for service)

    Copies to:

    Michael J. Aiello, Esq.

    Sachin Kohli, Esq.

    Weil, Gotshal & Manges LLP

    767 Fifth Avenue

    New York, New York 10153

    (212) 310-8000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     
     


    EXPLANATORY NOTE

    DEREGISTRATION OF SHARES

    Dynavax Technologies Corporation, a Delaware corporation (the “Registrant”), is filing with the U.S. Securities and Exchange Commission these post-effective amendments (the “Post-Effective Amendments”) to deregister all shares of common stock, par value $0.001 per share, of the Registrant (the “Shares”), previously registered under the following Registration Statements on Form S-8 (the “Registration Statements”), together with any and all plan interests and other securities registered thereunder:

     

      •  

    Registration Statement No 333-113220, filed on March 2, 2004, relating to the registration of 1,532,527 Shares under the Dynavax Technologies Corporation 1997 Equity Incentive Plan, 3,500,000 Shares under the Dynavax Technologies Corporation 2004 Stock Incentive Plan (“2004 SIP”) and 250,000 Shares under the Dynavax Technologies Corporation 2004 Employee Stock Purchase Plan (“2004 ESPP”);

     

      •  

    Registration Statement No. 333-136345, filed on August 4, 2006, relating to the registration of 800,000 Shares under the 2004 SIP and 246,000 Shares under the 2004 ESPP;

     

      •  

    Registration Statement No. 333-145094, filed on August 3, 2007, relating to the registration of 400,000 Shares under the 2004 SIP;

     

      •  

    Registration Statement No. 333-152819, filed on August 6, 2008, relating to the registration of 400,000 Shares under the 2004 SIP;

     

      •  

    Registration Statement No. 333-157741, filed on March 6, 2009, relating to the registration of 400,000 Shares under the 2004 SIP;

     

      •  

    Registration Statement No. 333-164255, filed on January 8, 2010, relating to the registration of 400,000 Shares under the 2004 SIP, 250,000 Shares under the 2004 ESPP, and 1,500,000 Shares under the Dynavax Technologies Corporation 2010 Employment Inducement Award Plan;

     

      •  

    Registration Statement No. 333-171552, filed on January 6, 2011, relating to the registration of 15,000,000 Shares under the Dynavax Technologies Corporation 2011 Equity Incentive Plan, as amended, and 250,000 Shares under the 2004 ESPP;

     

      •  

    Registration Statement No. 333-190313, filed on August 1, 2013, relating to the registration of 10,000,000 Shares under the Dynavax Technologies Corporation Amended and Restated 2011 Equity Incentive Plan (“A&R 2011 EIP”);

     

      •  

    Registration Statement No. 333-197838, filed on August 4, 2014, relating to the registration of 500,000 Shares under the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan, as amended;

     

      •  

    Registration Statement No. 333-204506, filed on May 28, 2015, relating to the registration of 2,250,000 Shares under the A&R 2011 EIP;

     

      •  

    Registration Statement No. 333-211747, filed on June 1, 2016, relating to the registration of 3,200,000 Shares under the A&R 2011 EIP and 200,000 Shares under the Dynavax Technologies Corporation Amended and Restated 2014 Employee Stock Purchase Plan (“A&R 2014 ESPP”);

     

      •  

    Registration Statement No. 333-218470, filed on June 2, 2017, relating to the registration of 1,600,000 Shares under the A&R 2011 EIP;

     

      •  

    Registration Statement No. 333-221832, filed on November 30, 2017, relating to the registration of 1,200,000 Shares under the Dynavax Technologies Corporation 2017 Inducement Award Plan;


      •  

    Registration Statement No. 333-225525, filed on June 8, 2018, relating to the registration of 600,000 Shares under the A&R 2014 ESPP and 12,617,869 Shares under the Dynavax Technologies Corporation 2018 Equity Incentive Plan, as amended;

     

      •  

    Registration Statement No. 333-233247, filed on August 13, 2019, relating to the registration of 2,300,000 Shares under the Dynavax Technologies Corporation Amended and Restated 2018 Equity Incentive Plan (“A&R 2018 EIP”);

     

      •  

    Registration Statement No. 333-241674, filed on August 6, 2020, relating to the registration of 7,600,000 Shares under the A&R 2018 EIP;

     

      •  

    Registration Statement No. 333-253515, filed on February 25, 2021, relating to the registration of 1,500,000 Shares under the Dynavax Technologies Corporation 2021 Inducement Award Plan;

     

      •  

    Registration Statement No. 333-528469, filed on August 4, 2021, relating to the registration of 1,000,000 Shares under the A&R 2014 ESPP and 1,750,000 Shares under the Dynavax Technologies Corporation 2021 Inducement Award Plan;

     

      •  

    Registration Statement No. 333-265373, filed on June 2, 2022, relating to the registration of 15,000,000 Shares under the A&R 2018 EIP; and

     

      •  

    Registration Statement No. 333-281307, filed on August 6, 2024, relating to the registration of 11,400,000 Shares under the A&R 2018 EIP.

    On February 10, 2026, pursuant to the terms of the Agreement and Plan of Merger, dated as of December 23, 2025, by and among the Registrant, Sanofi, a French société anonyme (“Sanofi”) and Samba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Genzyme (“Purchaser”), Purchaser merged with and into the Registrant with the Registrant surviving the merger as a wholly owned subsidiary of Genzyme (the “Merger”).

    As a result of the Merger, the Registrant has terminated all offerings and sales pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, the Registrant hereby amends the Registration Statements to remove from registration the Shares registered but remaining unsold under the Registration Statements.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Emeryville, State of California, on February 10, 2026.

     

    DYNAVAX TECHNOLOGIES CORPORATION
    By:  

    /s/ Thomas Grenier

    Name:   Thomas Grenier
    Title:   Vice President

    Pursuant to Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

    Get the next $DVAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVAX

    DatePrice TargetRatingAnalyst
    2/11/2025$15.00 → $12.00Neutral → Sell
    Goldman
    2/1/2024$20.00Neutral
    Goldman
    9/27/2022$22.00Mkt Outperform
    JMP Securities
    1/6/2022$38.00Buy
    Goldman
    12/29/2021$23.00 → $28.00Buy
    HC Wainwright & Co.
    8/31/2021$20.00 → $23.00Buy
    HC Wainwright & Co.
    8/6/2021$19.00Buy
    Goldman Sachs
    8/5/2021$16.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DVAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

    Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price onDecember 23, 2025 EMERYVILLE, Calif., Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (NASDAQ:DVAX), a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. The acquisition augments Sanofi's presence in adult immunization by bringing together Dynavax's vaccines with Sanofi's global scale, development capabilities and commercial reach.

    12/24/25 1:23:00 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

    EMERYVILLE, Calif., Nov. 19, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd at 2:10 p.m. ET. The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. About DynavaxDynavax is a

    11/19/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    SEC Filings

    View All

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 4:26:50 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 4:25:59 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Dynavax Technologies Corporation

    S-8 POS - DYNAVAX TECHNOLOGIES CORP (0001029142) (Filer)

    2/10/26 4:24:39 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Emini Emilio returned 10,075 units of Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    2/10/26 4:15:20 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Myers Scott Dunseth returned 31,204 units of Common Stock - Restricted Stock Units to the company, closing all direct ownership in the company (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    2/10/26 4:15:20 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VP, Chief Accounting Officer Metzinger Joseph Anthony closing all direct ownership in the company (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    2/10/26 4:15:25 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Myers Scott Dunseth bought $41,116 worth of shares (3,800 units at $10.82), increasing direct ownership by 12% to 35,004 units (SEC Form 4)

    4 - DYNAVAX TECHNOLOGIES CORP (0001029142) (Issuer)

    8/25/25 8:50:44 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dynavax downgraded by Goldman with a new price target

    Goldman downgraded Dynavax from Neutral to Sell and set a new price target of $12.00 from $15.00 previously

    2/11/25 7:05:05 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Dynavax with a new price target

    Goldman initiated coverage of Dynavax with a rating of Neutral and set a new price target of $20.00

    2/1/24 6:20:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on Dynavax with a new price target

    JMP Securities initiated coverage of Dynavax with a rating of Mkt Outperform and set a new price target of $22.00

    9/27/22 7:39:04 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Leadership Updates

    Live Leadership Updates

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deep Track Capital Comments on ISS Recommendation

    Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees Deep Track Capital, LP, (together with its affiliates, "Deep Track" or "we"), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax", "DVAX" or the "Company"), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Instit

    5/23/25 6:12:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

    ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleading Supplemental Materials Urges Stockholders to Follow ISS Recommendation and Vote "FOR" ALL Four of Dynavax's Highly Qualified Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif., May 23, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that leading independent proxy advisory firm, Institutional Shareholder Services ("ISS

    5/23/25 1:44:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Financials

    Live finance-specific insights

    View All

    Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

    HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; reiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 millionBoard of Directors authorizes new $100 million share repurchase program Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunitiesConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Nov. 5, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vacc

    11/5/25 4:01:00 PM ET
    $DVAX
    $VXRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

    EMERYVILLE, Calif., Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Wednesday, November 5, 2025, at 4:30 p.m. ET/1:30 p.m. PT. The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://in

    10/22/25 4:01:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dynavax Reports Second Quarter 2025 Financial Results

    Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growthRefines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 millionTop-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant programConference call today at 4:30 p.m. ET/1:30 p.m. PTEMERYVILLE, Calif., Aug. 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ:DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today reported financial results and provided a business update

    8/7/25 4:00:00 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DVAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Dynavax Technologies Corporation

    SC 13G - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    11/14/24 12:18:08 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dynavax Technologies Corporation

    SC 13D/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/24/24 4:06:57 PM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dynavax Technologies Corporation

    SC 13G/A - DYNAVAX TECHNOLOGIES CORP (0001029142) (Subject)

    10/16/24 9:37:13 AM ET
    $DVAX
    Biotechnology: Pharmaceutical Preparations
    Health Care